Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer

Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer

Men who develop metastatic castration-resistant prostate cancer (CRPC) invariably succumb to the disease. The development and progression to CRPC following androgen ablation therapy is predominantly driven by unregulated androgen receptor (AR) signaling1-3. Despite the success of recently approved t...

Full description

Bibliographic Details
Main Authors: Asangani, Irfan A., Dommeti, Vijaya L., Wang, Xiaoju, Malik, Rohit, Cieslik, Marcin, Yang, Rendong, Escara-Wilke, June, Wilder-Romans, Kari, Dhanireddy, Sudheer, Engelke, Carl, Iyer, Mathew K., Jing, Xiaojun, Wu, Yi-Mi, Cao, Xuhong, Qin, Zhaohui S., Wang, Shaomeng, Feng, Felix Y., Chinnaiyan, Arul M.
Format: Online
Language:English
Published: 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075966/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075966/

Similar Items